FTC Greenlights Barr's $2.5B Takeover Of Pliva
The U.S. Federal Trade Commission has signed off on Barr Pharmaceuticals' $2.5 billion acquisition of European generic drug giant Pliva on the condition that Barr sell the rights to four of...To view the full article, register now.
Already a subscriber? Click here to view full article